Our licensing partner Verrica Pharmaceuticals today announced that the first patient has been dosed in Part 2 of their Phase II study evaluating our lead compound, LTX-315 - by Verrica. | April 12, 2023
Accepted abstracts include three summarizing findings from separate, large-scale, real-world studies evaluating clinical utility of Decipher Prostate Genomic Classifier
. | April 12, 2023
By Kirk Maltais Corn for May delivery rose 0.8%, to $6.56 a bushel, on the Chicago Board of Trade on Wednesday, with traders evaluating supplies as tight even though the USDA didn t cut its. | April 12, 2023
BELLUS Health Inc. announced positive data from its Phase 1 bioavailability equivalence study evaluating a once-daily Extended-Release formulation of camlipixant in comparison to a twice-daily. | April 6, 2023
Continued advancement of global patient enrollment with approvals and site activations in the U.S., Switzerland, France, Spain and ItalyEnrollment continuing to progress toward an interim analysis expected